Behind the Scenes with CROs: What biotechs need to know
EARLY ENGAGEMENT AND INCREASED TRANSPARENCY GARNER BETTER OUTCOMES FOR BIOTECHS AND PATIENTS
Patients rely on the effective relationships between innovative biotech and CROs to bring new, life-changing therapeutics to them. Dan Burch, M.D., MBA, Global Head of PPD® Biotech, shares perspectives from leadership roles at both biotech and CROs about evolving models and how close, proactive communication can help identify innovative directions to improve efficiency and outcomes of trials, in a recent interview for the Chief Medical Officer 360 Newsletter.
The free exchange of information is a proactive way to maintain trusted relationships, identify new solutions and avoid the growth of undiscovered issues.
Daniel Burch, M.D., MBA, Global Head of PPD Biotech